Case report

Faure, Emmanuel; Galpérine, Tatiana; Cannesson, O.; Alain, Sophie; Gnemmi, Viviane; Goéminne, Céline; Dewilde, Annie; Béné, Johana; Lasri, Mohamed; Foy, Célia Lessoré de Sainte; Lionet, Arnaud

doi:10.1097/md.0000000000005226

Cited by 17 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brincidofovir: This experimental drug is a lipid conjugate of cidofovir with broad-spectrum antiviral activity. It achieves better oral bioavailability and intracellular concentrations than cidofovir [44][45][46]. It is also active at almost 400-times lower concentration than cidofovir [47].…”

Section: Therapeutic Agentsmentioning

confidence: 99%

“…It is also active at almost 400-times lower concentration than cidofovir [47]. Unlike cidofovir, brincidofovir appears to be significantly less nephrotoxic [44,46]. In patients who develop brincidofovir-induced nephropathy, kidney function quickly recovers after discontinuation of therapy [44].…”

Section: Therapeutic Agentsmentioning

confidence: 99%

“…The aforementioned studies addressing brincidofovir'sefficacy against CMV infection provide preliminary evidence for brincidofovir's role in therapy and therefore warrant further investigation [44,[50][51][52].…”

Section: Therapeutic Agentsmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacological Options for Viral Induced Hemorrhagic Cystitis Management: A Review of the Literature

Giles¹,

Wilder²,

Ritter³

et al. 2019

JPT

View full text Add to dashboard Cite

Background: Viral induced hemorrhagic cystitis (VIHC) is very common among patients who become immunocompromised following organ transplantation. However, there is neither consensus on the standard of care nor clear guidelines to aid in clinical decision making when treatment VIHC. This review discusses currently available pharmacologic agents, presents investigational drug therapies, and outlines alternative treatment options that could be effective against VIHC.Recent findings: Letermovir is a novel antiviral agent approved for CMV prophylaxis in patients post-hematopoietic stem cell transplantation (HSCT). Although no studies have yet been conducted in patients with VIHC, this new antiviral agent shows promise in preventing emergence of CMV in patients after HSCT. Additionally, newer studies addressing the efficacy of brincidofovir, an experimental drug derived from cidofovir, against CMV infection may provide preliminary evidence for brincidofovir’s role in therapy and therefore warrant further investigation.Conclusion: Polyoma BK virus (BKV), cytomegalovirus (CMV), and adenovirus (ADV) are the primary culprits for HC occurrence in patients undergoing renal transplantation or allogeneic HSCT. CMV-associated HC could be prevented or treated by ganciclovir and valganciclovir because these agents’ effectiveness has been clearly established in other non-HC infections related to CMV. ADV-associated HC could be mitigated by brincidofovir and ribavirin, however the high toxicity associated with these agents may be a limiting factor for their use. BKV-associated HC is best managed by cidofovir and leflunomide, but not by fluoroquinolones. Finally, intravesicular instillation should be preferred in patients who experience toxicities associated with systemic use of antivirals.

show abstract

Section: Therapeutic Agentsmentioning

confidence: 99%

Section: Therapeutic Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological Options for Viral Induced Hemorrhagic Cystitis Management: A Review of the Literature

Giles¹,

Wilder²,

Ritter³

et al. 2019

JPT

View full text Add to dashboard Cite

show abstract

“…Moreover, Faure et al . reported two cases of acute kidney injury in SOT patients who received brincidofovir 57 .…”

Section: Infections Acquired After Transplantation: New Treatments Avmentioning

confidence: 99%

Recent advances in understanding and managing infectious diseases in solid organ transplant recipients

2018

View full text Add to dashboard Cite

Background: Undergoing solid organ transplantation (SOT) exposes the recipient to various infectious risks, including possible transmission of pathogen by the transplanted organ, post-surgical infections, reactivation of latent pathogens, or novel infections. Recent advances: In the last few years, the emergence of Zika virus has raised concerns in the transplant community. Few cases have been described in SOT patients, and these were associated mainly with moderate disease and favorable outcome; the notable exception is a recent case of fatal meningo-encephalopathy in a heart transplant recipient. Because of the advances in treating hepatitis C, several teams recently started to use organs from hepatitis C-positive donors. The worldwide increasing incidence of multidrug-resistant pathogens, as well as the increasing incidence of Clostridioides difficile infection, is of particular concern in SOT patients. In the field of mycology, the main recent therapeutic advance is the availability of isavuconazole for the treatment of invasive aspergillosis and mucormycosis. This drug has the advantage of minimal interaction with calcineurin inhibitors. Regarding the viral reactivations occurring after transplant, cytomegalovirus (CMV) infection is still a significant issue in SOT patients. The management of resistant CMV remains particularly difficult. The approval of letermovir, albeit in bone marrow transplantation, and the therapeutic trial of maribavir bring a ray of hope. Another advancement in management of post-transplant infections is the development of in vitro tests evaluating pathogen-specific immune response, such as immunodiagnostics for CMV and, more recently, tests for monitoring immunity against BK virus. Conclusion: The increasing number of organ transplantations, the use of newer immunosuppressive drugs, and high-risk donors continue to define the landscape of transplant infectious diseases in the current era.

show abstract

“…In the article, “Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection” [ 1 ] , which appeared in Volume 95, Issue 44 of Medicine, the authors have requested a correction in Paragraph 1.1 line 23–24 where the recommendation should be changed from CHIMERIX to be in accordance with the French Society of Nephrology and Dialysis.…”

mentioning

confidence: 99%

Case report

2017

Medicine

View full text Add to dashboard Cite

Case report

Cited by 17 publications

References 18 publications

Pharmacological Options for Viral Induced Hemorrhagic Cystitis Management: A Review of the Literature

Pharmacological Options for Viral Induced Hemorrhagic Cystitis Management: A Review of the Literature

Recent advances in understanding and managing infectious diseases in solid organ transplant recipients

Case report

Contact Info

Product

Resources

About